ILARIS sol inj 150 mg/ml flac 1 ml

7680661910011 CH-66191 L04AC08 07.15.0.

Reimbursement limitations:

ILARIS.01

Syndromes périodiques associés à la cryopyrine (CAPS):
Après la garantie de la prise en charge …

ILARIS sol inj 150 mg/ml flac 1 ml
ILARIS sol inj 150 mg/ml flac 1 ml
ILARIS sol inj 150 mg/ml flac 1 ml
1 / 3
google

Details

Product number
6619101
CPT
-
Packaging group
1
Unit
Durchstechflasche(n)
Composition
canakinumabum 150 mg, mannitolum, histidinum aut histidini hydrochloridum monohydricum, polysorbatum 80, aqua ad iniectabile q.s. ad solutionem pro 1 ml.

Articles (1)

Ilaris, Injektionslösung
Injektionslösung
1
View

Official Swissmedic V2 data

Additional information from the official database

Official medical documents

Patient information leaflet
Allemand
08/10/2021
Patient information leaflet
Français
08/10/2021
Patient information leaflet
Italien
08/10/2021
Professional SmPC
Allemand
08/10/2021
Professional SmPC
Français
08/10/2021
Professional SmPC
Italien
08/10/2021

Detailed composition

Substance Quantity Type Category
(N/A)
150.0 MG Substance Wirkstoff (Principe actif)
(N/A)
- Substance HNIDK
(N/A)
- Substance HNIDK
(N/A)
- Substance HNIDK
(N/A)
- Substance HNIDK
(N/A)
- Substance HNIDK

Reimbursement information

Public price
CHF 10954.95
Specialties list
Yes
Generic
No

Reimbursement limitation

SL addition date: 01/12/2017

Authorization holder

Novartis Pharma Schweiz AG

6343 Risch

Authorization information

Swissmedic authorization number
66191
Drug name
Ilaris, Injektionslösung
Galenic form
LSINJ
ATC Code
L04AC08
Authorization status
Z
Dispensation category
A
First authorization
15/05/2017
Authorization expiration date
31/12/9999
IT number
07.15.0.
Domain
Human medicine
Field of application
Cryopyrin-assoziierte Periodische Syndrome (CAPS) wie des Muckle-Wells-Syndroms (MWS), des familiären autoinflammatorischen Kälte-Syndroms (FACS) / der familiären Kälteurtikaria (FCU) und der multisystemischen entzündlichen Erkrankung mit Beginn im Neugeborenenalter (NOMID)/des chronischen infantilen neuro-dermo-artikulären Syndroms (CINCA). Tumornekrosefaktor-Rezeptor-assoziiertes periodisches Syndrom (TRAPS). Hyperimmunglobulin-D-Syndrom (HIDS) / Mevalonatkinasedefizienz (MKD). Familiäres Mittelmeerfieber (FMF). Systemische juvenile idiopathische Arthritis (SJIA). Adultes Still-Syndrom.

Packaging details

Description (FR)
ILARIS sol inj 150 mg/ml flac 1 ml
Description (DE)
ILARIS Inj Lös 150 mg/ml Durchstf 1 ml
Market launch
15/05/2017
Narcotic (BTM)
No